202 related articles for article (PubMed ID: 28667408)
41. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
Kataoka H; Mori Y; Shimura T; Nishie H; Natsume M; Mochizuki H; Hirata Y; Sobue S; Mizushima T; Sano H; Mizuno Y; Nakamura M; Hirano A; Tsuchida K; Adachi K; Seno K; Kitagawa M; Kawai T; Joh T
Cancer Chemother Pharmacol; 2016 May; 77(5):957-62. PubMed ID: 27002325
[TBL] [Abstract][Full Text] [Related]
42. Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701).
Nakanishi K; Kobayashi D; Mochizuki Y; Ishigure K; Ito S; Kojima H; Ishiyama A; Fujitake S; Shikano T; Morita S; Kodera Y
Int J Clin Oncol; 2016 Jun; 21(3):557-65. PubMed ID: 26547424
[TBL] [Abstract][Full Text] [Related]
43. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer.
Shinchi H; Maemura K; Mataki Y; Kurahara H; Sakoda M; Ueno S; Hiraki Y; Nakajo M; Natsugoe S; Takao S
J Hepatobiliary Pancreat Sci; 2012 Mar; 19(2):152-8. PubMed ID: 21647560
[TBL] [Abstract][Full Text] [Related]
44. Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma.
Yamanaka T; Matsumoto S; Teramukai S; Ishiwata R; Nagai Y; Fukushima M
Br J Cancer; 2007 Jul; 97(1):37-42. PubMed ID: 17551497
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
[TBL] [Abstract][Full Text] [Related]
46. Effect of the weekly administration of liposome-Paclitaxel combined with s-1 on advanced gastric cancer.
Chen L; Chen Q; Zhuang Z; Zhang Y; Tao J; Shen L; Shen X; Chen Z; Wang J; Zhu M; Wang H
Jpn J Clin Oncol; 2014 Mar; 44(3):208-13. PubMed ID: 24453274
[TBL] [Abstract][Full Text] [Related]
47. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
Jeung HC; Rha SY; Im CK; Shin SJ; Ahn JB; Yang WI; Roh JK; Noh SH; Chung HC
Cancer; 2011 May; 117(10):2050-7. PubMed ID: 21523716
[TBL] [Abstract][Full Text] [Related]
48. [A case of type 4 gastric cancer with peritoneal dissemination successfully treated over 2 years by alternate-day administration of TS-1].
Arai W; Hosoya Y; Yokoyama T; Saito S; Hirashima Y; Hyodo M; Yasuda Y; Nagai H; Shirasaka T
Gan To Kagaku Ryoho; 2004 Feb; 31(2):237-40. PubMed ID: 14997759
[TBL] [Abstract][Full Text] [Related]
49. Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer.
Kochi M; Fujii M; Kanamori N; Kaiga T; Takahashi T; Kobayashi M; Takayama T
J Cancer Res Clin Oncol; 2006 Dec; 132(12):781-5. PubMed ID: 16804723
[TBL] [Abstract][Full Text] [Related]
50. Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).
Miura Y; Sukawa Y; Hironaka S; Mori M; Nishikawa K; Tokunaga S; Okuda H; Sakamoto T; Taku K; Nishikawa K; Moriwaki T; Negoro Y; Kimura Y; Uchino K; Shinozaki K; Shinozaki H; Musha N; Yoshiyama H; Tsuda T; Miyata Y; Sugimoto N; Shirakawa T; Ito M; Yonesaka K; Yoshimura K; Boku N; Nosho K; Takano T; Hyodo I
Gastric Cancer; 2018 Jan; 21(1):84-95. PubMed ID: 28497176
[TBL] [Abstract][Full Text] [Related]
51. S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects.
Takahashi I; Kakeji Y; Emi Y; Sakurai M; Yonemura Y; Kimura Y; Maehara Y
Gastric Cancer; 2003; 6 Suppl 1():28-33. PubMed ID: 12775017
[TBL] [Abstract][Full Text] [Related]
52. [An elderly patient with advanced gastric cancer maintaining complete response for over 3 years by oral administration of UFT following short span of S-1].
Yamanaka T; Okabe K; Sugiyama S; Sano O; Wada A; Beppu T; Baba H
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2424-6. PubMed ID: 21224594
[TBL] [Abstract][Full Text] [Related]
53. Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer.
Shiroyama T; Kijima T; Komuta K; Yamamoto S; Minami S; Ogata Y; Okafuji K; Imamura F; Hirashima T; Tachibana I; Kawase I; Kumanogoh A
Cancer Chemother Pharmacol; 2012 Dec; 70(6):783-9. PubMed ID: 22960985
[TBL] [Abstract][Full Text] [Related]
54. S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial.
Du F; Zheng Z; Shi S; Jiang Z; Qu T; Yuan X; Sun Y; Song Y; Yang L; Zhao J; Wang J; Chi Y
Medicine (Baltimore); 2015 Jun; 94(23):e958. PubMed ID: 26061330
[TBL] [Abstract][Full Text] [Related]
55. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
[TBL] [Abstract][Full Text] [Related]
56. [Efficacy of lobaplatin plus S-1 and the predictive value of circulating tumor cell in patients with advanced gastric cancer].
Feng Q; Zhao JR; Zhang AX; Li SL
Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):696-702. PubMed ID: 30293397
[No Abstract] [Full Text] [Related]
57. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
[TBL] [Abstract][Full Text] [Related]
58. A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer.
Hokita S; Aikou T; Miyazono F; Ishigami S; Aridome K; Maenohara S; Saihara T; Suenaga K; Nomura H; Maeda S; Takatori H; Arima H; Uchikado Y; Natsugoe S; Takao S
Cancer Chemother Pharmacol; 2006 Jun; 57(6):736-40. PubMed ID: 16163539
[TBL] [Abstract][Full Text] [Related]
59. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.
Lenz HJ; Lee FC; Haller DG; Singh D; Benson AB; Strumberg D; Yanagihara R; Yao JC; Phan AT; Ajani JA
Cancer; 2007 Jan; 109(1):33-40. PubMed ID: 17133415
[TBL] [Abstract][Full Text] [Related]
60. [Indication of alternate-day treatment with S-1 in patients with oral cancer].
Negishi A; Ogawa M; Kosugi K; Takayama Y; Gomi A; Miyazaki H; Yokoo S
Gan To Kagaku Ryoho; 2015 May; 42(5):569-73. PubMed ID: 25981649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
